Restasis and Pancytopenia aggravated - a phase IV clinical study of FDA data

Summary:

Pancytopenia aggravated is reported as a side effect among people who take Restasis (cyclosporine), especially for people who are female, 60+ old, also take Tylenol, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Pancytopenia aggravated when taking Restasis. It is created by eHealthMe based on reports of 34,716 people who have side effects when taking Restasis from the FDA, and is updated regularly.

What is Restasis?

Restasis has active ingredients of cyclosporine. It is often used in dry eyes. eHealthMe is studying from 35,199 Restasis users. Check the latest studies of Restasis.

What is Pancytopenia aggravated?

Pancytopenia aggravated (serious medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets) is found to be associated with 1,331 drugs and 641 conditions by eHealthMe. Check the latest studies of Pancytopenia aggravated.

On Jul, 26, 2026

34,716 people reported to have side effects when taking Restasis.
Among them, 25 people (0.07%) have Pancytopenia aggravated.

Could Restasis cause Pancytopenia aggravated?

Among these 25 people:

What is the gender of people who have Pancytopenia aggravated when taking Restasis? *

female: 70.83 %
male: 29.17 %

What is the age of people who have Pancytopenia aggravated when taking Restasis? *

What are other drugs people take besides Restasis? *

What are other side effects people have besides Pancytopenia aggravated? *

Febrile Neutropenia (fever with reduced white blood cells): 6 people, 24.00%
Pneumonia: 5 people, 20.00%
Gastritis (inflammation of stomach): 3 people, 12.00%
Clostridium Difficile Colitis (inflammation of colon by clostridium difficile bacteria infection): 3 people, 12.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 12.00%
Pleural Effusion (water on the lungs): 3 people, 12.00%
Oedema Peripheral (superficial swelling): 3 people, 12.00%
Neuropathy Peripheral (surface nerve damage): 3 people, 12.00%
Thrombocytopenia (decrease of platelets in blood): 3 people, 12.00%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 3 people, 12.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 12 people, 48.00%
Nausea (feeling of having an urge to vomit): 6 people, 24.00%
Pain: 5 people, 20.00%
Constipation: 5 people, 20.00%
Fever: 4 people, 16.00%
Sleep Disorder: 2 people, 8.00%
Hypotension (abnormally low blood pressure): 2 people, 8.00%
Back Pain: 2 people, 8.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 2 people, 8.00%
Cough: 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Restasis and have Pancytopenia aggravated?

- Check whether Pancytopenia aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Restasis:

Restasis (35,199 reports)

Browse all side effects of Restasis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pancytopenia aggravated:

Pancytopenia aggravated (1,331 drugs)

Browse all the conditions that are associated with Pancytopenia aggravated:

Pancytopenia aggravated (641 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on cyclosporine (the active ingredients of Restasis) and Restasis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.